{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"27.8","value":"15.6"},{"comment":"Median OS was not reached. The upper bound of the OS confidence interval is not available due to insufficient observed events at this time.","groupId":"OG001","lowerLimit":"9.7","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive:\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG000","title":"9-ING-41 + Carboplatin (Part I)"},{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy).\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG001","title":"Pembrolizumab + 9-ING-41 + Carboplatin (Part II)"}],"paramType":"MEDIAN","populationDescription":"Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.","reportingStatus":"POSTED","timeFrame":"Up to 38.1 months","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}